Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18314263 | 0.86 | RARB (0.40) | FFAR4PTPN1RARBTSHRTHRA | |
| SCHEMBL9399219 | 0.83 | RARB (0.57) | RARBTSHRRARARARG | |
| SCHEMBL9399803 | 0.83 | RARB (0.57) | RARBTSHRRARARARG | |
| SCHEMBL18314440 | 0.83 | RARB (0.66) | RARBTSHRRARAPTPN11 | |
| SCHEMBL18314304 | 0.82 | FFAR4 (0.39) | FFAR4RARBTHRATHRBRARA | |
| SCHEMBL7789312 | 0.82 | SOAT1 (0.49) | SOAT1LTA4HPTPN1RARBTSHR | |
| SCHEMBL7786753 | 0.81 | PTPN11 (0.53) | SOAT1PTPN1RARBTHRATHRB | |
| SCHEMBL7788886 | 0.81 | PTPN11 (0.53) | SOAT1PTPN1RARBTHRATHRB | |
| SCHEMBL15564752 | 0.79 | TSHR (0.47) | LTA4HPTPN1TSHR | |
| SCHEMBL9399575 | 0.78 | RARB (0.55) | RARBTSHRRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9441164-B2 | Isosorbide derivative, liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150034868-A1 | ISOSORBIDE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150034868-A1 | ISOSORBIDE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | AR, NR3C2, RCC2 | SOAT1 4726/4885FFAR4 54/4885LTA4H 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.